Anfield Capital Management, LLC Halozyme Therapeutics, Inc. Transaction History

Anfield Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	SELL	$40.06 - $59.44 $32,849 - $48,740	-820 Reduced 72.44%	312 $17,000
Q3 2022 Nov 09, 2022	BUY	$38.53 - $51.78 $1,502 - $2,019	39 Added 3.57%	1,132 $45,000
Q2 2022 Aug 09, 2022	BUY	$37.35 - $48.3 $5,826 - $7,534	156 Added 16.65%	1,093 $48,000
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $21,419 - $27,510	670 Added 250.94%	937 $37,000
Q4 2021 Feb 03, 2022	BUY	$31.82 - $40.75 $7,827 - $10,024	246 Added 1171.43%	267 $11,000
Q3 2021 Nov 04, 2021	BUY	$38.47 - $46.42 $807 - $974	21 New	21 $1,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Anfield Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Anfield Capital Management, LLC with notifications on news.